Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-113-8 | CAS number: 7787-41-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 30th Novemebr 2017 - 27th December 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 bis (Acute Oral Toxicity - Fixed Dose Procedure)
- GLP compliance:
- yes
- Test type:
- fixed dose procedure
- Limit test:
- no
Test material
- Reference substance name:
- Barium selenate
- EC Number:
- 232-113-8
- EC Name:
- Barium selenate
- Cas Number:
- 7787-41-9
- Molecular formula:
- Ba.H2O4Se
- IUPAC Name:
- barium selenate
- Test material form:
- solid: crystalline
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Lewer Corporation Batch Number: 20170425
- Expiration date of the lot/batch: 24th April 2019
- Purity test date: 97.6%
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: 15 to 25° C, protected from light.
- Stability under test conditions: Stable
- Solubility and stability of the test substance in the solvent/vehicle: Test item administered as a dispersion (see below), test item stable in the vehicle.
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: not applicable
- Preliminary purification step (if any): not applicable
- Final preparation of a solid: Test item dispersed in 1% w/v methylcellulose.
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd Margate, Kent
- Age at study initiation: 10-12 weeks
- Weight at study initiation: 210 - 222g
- Fasting period before study: overnight
- Housing:In compliance with ‘Code of Practice for the Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes ‘ (Home Office, London, 2014)
- Diet: ad libitum with the exception of the fasting period.
- Water: ad libitum
- Acclimation period: 6 - 13 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C):20 - 24
- Humidity (%):45 - 65
- Air changes (per hr):15 - 20
- Photoperiod (hrs dark / hrs light):12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- methylcellulose
- Doses:
- Sighting study performed using single doses at 50 mg/kg and 300 mg/kg.
Based on the results of the sighting study a further 4 animals were dosed at 300 mg/kg. - No. of animals per sex per dose:
- 1 female animal at 50 mg/kg
5 female animals at 300 mg/kg. - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical signs were recorded 15 and 30 minutes post teatment, hourly between 1 and 4 hours, twice daily on days 2,3 and 4 and once daily from 5th day to the end of the observation period. Body weights were recorded on days 1,4,8 and 15 post treatment.
- Necropsy of survivors performed: Yes
- Other examinations performed: Not applicable
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- ca. 500 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: LD50 quoted from the CLP Regulation Section 3.1.3.6.2.3, on the basis of the classification being determined as Acute Tox 4 from the study results.
- Mortality:
- 50 mg/kg - 0/1
300 mg/kg - 1/5 (Day 2) - Clinical signs:
- other: 50 mg/kg: No clinical signs observed. 300 mg/kg - hunched posture, piloerection, ataxia, deceased activity, pallor of the extremities and ptosis. The clinical signs developed from 2 hours after dosing up to day 7.
- Gross pathology:
- Animals that died during the study - No macroscopic changes
Surviving animals - One animal out of the four survivng showed pelvic dilation of the kidney.
Any other information on results incl. tables
See attached document below for results tables.
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The results of the fixed dose oral toxicity study on barium selenate conclude the requirement to classify the test substance as Acute Toxicity Category 4 according to the Globally Harmonised System of Classification of Chemicals.
- Executive summary:
A GLP study was performed to assess the toxicity of Barium Selenate when administered orally. The study was performed in accordance with OECD guideline 420 following a fixed dose procedure. Initially single female rats were dosed at 50 mg/kg bw/day and 300 mg/kg bw/day. No mortality or signs of toxicity were observed at 50 mg/kg bw/day; therefore a further 4 female animals were dosed at 300 mg/kg bw/day.
The animals were observed for 14 days after dosing. All animals were subject to a gross pathological examination.
One animal died after dosing with 300 mg/kg bw/day on day 2. No clinical signs were observed in animals dosed with 50 mg/kg bw/day, animals dosed with 300 mg/kg bw/day exhibited hunched posture, piloerection, ataxia, deceased activity, pallor of the extremities and ptosis. The clinical signs developed from 2 hours after dosing up to day 7.
All surviving animals showed either no change or a decrease in body weights over the first week of the observation period, followed by a gain in body weight during the second week of observation.
No macroscopic changes were observed in the animal that died during the study, one of the surviving 4 animals dosed with 300 mg/kg bw/day showed pelvic dilation of the kidney.
Based on the results of the study, the test substance barium selenate is classified as Acute Toxicity Category 4 according to the Globally Harmonised System of Classification of Chemicals.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.